GH001 Shows Promising Results in Treatment-Resistant Depression Study
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy GHRS?
Source: Newsfilter
- Clinical Trial Results Published: GH Research PLC has published the Phase 2b trial results of GH001 in JAMA Psychiatry, demonstrating significant efficacy in treatment-resistant depression (TRD) patients, achieving the primary endpoint with a MADRS reduction of 15.5 points from baseline (P<0.0001), indicating GH001's potential to transform current treatment paradigms.
- Efficacy Independence Analysis: A forthcoming article in Psychopharmacology Bulletin highlights that GH001's efficacy is independent of prior antidepressant treatment failures, with Day 8 remission rates ranging from 53.9% to 63.6% among patients with 2 to 5 prior failures, showcasing GH001's unique advantage.
- Long-Term Remission Rate Improvement: At the end of the trial, 6-month remission rates reached 61.5% to 85.7% in the same patient groups, contrasting sharply with the declining remission rates observed in the STAR*D trial with successive treatment failures, suggesting GH001 may offer new hope for patients with extensive treatment histories.
- Advancement of Global Trial Plans: CEO Velichka Valcheva stated that the publication in JAMA Psychiatry provides independent peer-reviewed validation of GH001's Phase 2b findings, supporting the company's efforts to advance GH001 into global pivotal trials, signaling future strategic positioning in the depression treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GHRS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GHRS
Wall Street analysts forecast GHRS stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.390
Low
19.00
Averages
28.60
High
35.00
Current: 13.390
Low
19.00
Averages
28.60
High
35.00
About GHRS
GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. The Company's pipeline includes GH001, GH002 and GH003. The Company focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Company has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). The GH002 is a 5-MeO-DMT product candidate formulated for administration via an injectable approach. GH002 has completed pre-clinical development to support early clinical trials. The GH003 is a 5-MeO-DMT product candidate formulated for administration via an intranasal administration approach.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GH001 Shows Promising Results in Treatment-Resistant Depression Study
- Clinical Trial Results Published: GH Research PLC has published the Phase 2b trial results of GH001 in JAMA Psychiatry, demonstrating significant efficacy in treatment-resistant depression (TRD) patients, achieving the primary endpoint with a MADRS reduction of 15.5 points from baseline (P<0.0001), indicating GH001's potential to transform current treatment paradigms.
- Efficacy Independence Analysis: A forthcoming article in Psychopharmacology Bulletin highlights that GH001's efficacy is independent of prior antidepressant treatment failures, with Day 8 remission rates ranging from 53.9% to 63.6% among patients with 2 to 5 prior failures, showcasing GH001's unique advantage.
- Long-Term Remission Rate Improvement: At the end of the trial, 6-month remission rates reached 61.5% to 85.7% in the same patient groups, contrasting sharply with the declining remission rates observed in the STAR*D trial with successive treatment failures, suggesting GH001 may offer new hope for patients with extensive treatment histories.
- Advancement of Global Trial Plans: CEO Velichka Valcheva stated that the publication in JAMA Psychiatry provides independent peer-reviewed validation of GH001's Phase 2b findings, supporting the company's efforts to advance GH001 into global pivotal trials, signaling future strategic positioning in the depression treatment landscape.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that patients receiving the 20 mg dose achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential as an adjunctive treatment for generalized anxiety disorder.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of major depressive disorder patients being treatment-resistant, driving urgent demand for novel therapeutic mechanisms that Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline and safeguarding its research activities in the mental health sector from financial constraints.
- Enhanced Leadership: The appointment of Dr. Freda Lewis-Hall to Helus Pharma's Board and as Chair of the Scientific Advisory Committee, leveraging her extensive experience at Pfizer, is expected to provide crucial guidance for the company's scientific development and market strategy.
See More
GH Research Reports FY 2025 Financial Results
- Financial Performance: GH Research reported a FY 2025 GAAP EPS of -$0.79, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, the company held $280.7 million in cash, cash equivalents, and marketable securities, maintaining sufficient liquidity to support future R&D and operations despite the reported losses.
- FDA Progress: GH001 shows robust data ahead of the FDA IND decision, potentially opening new market opportunities; if approved, it could enhance the company's competitiveness in the depression treatment sector.
- Clinical Trial Update: Following the FDA lifting the clinical hold on its depression therapy, GH Research's stock surged, indicating that the upcoming late-stage trial update may further increase market interest in its products.
See More
Helus Pharma Advances Mental Health Drug Development
- Clinical Trial Progress: Helus Pharma's SPL026 showed significant efficacy in a randomized Phase 2 trial for major depressive disorder, with a mean MADRS score reduction of 7.35 in the 21.5 mg dose group among 34 participants, indicating its potential in the mental health sector.
- New Drug Development: The company is advancing HLP003 through Phase 3 trials, which has received FDA Breakthrough Therapy Designation, with preliminary data showing a 100% response rate and 71% remission rate at 12 months, highlighting its importance in treating major depressive disorder.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash reserves, providing strong financial backing for the continued advancement of its multi-asset clinical pipeline, ensuring sustainability for future R&D efforts.
- Market Outlook: As regulatory approvals for mental health drugs draw closer, Helus Pharma and its peers are reshaping the market perception of psychedelic drugs, which is expected to create significant commercial opportunities and enhance market share for the company.
See More
Helus Pharma Advances Psychedelic Drug Clinical Trials
- Clinical Trial Progress: Helus Pharma's SPL026 achieved a mean MADRS difference of -7.35 (p=0.023) in a randomized Phase 2 trial involving 34 participants with major depressive disorder, indicating significant efficacy and potential in the mental health sector.
- Drug Development Strategy: Helus Pharma's HLP003 has received FDA Breakthrough Therapy Designation and is advancing through two pivotal Phase 3 studies, with topline data expected in Q4 2026, showcasing the company's ongoing innovation and competitiveness in depression treatment.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline, demonstrating a strong financial foundation for R&D efforts.
- Industry Recognition: A consensus statement from the U.S. National Network of Depression Centers indicates that academia is preparing to integrate psychedelics into routine clinical practice, reflecting the growing acceptance of Helus Pharma and its peers in the mental health treatment landscape.
See More
GH001 Shows Promising Results in Treatment-Resistant Depression Study
- Clinical Trial Results Published: GH Research PLC has published the Phase 2b trial results of GH001 in JAMA Psychiatry, demonstrating significant efficacy in treatment-resistant depression (TRD) patients, achieving the primary endpoint with a MADRS reduction of 15.5 points from baseline (P<0.0001), indicating GH001's potential to transform current treatment paradigms.
- Efficacy Independence Analysis: A forthcoming article in Psychopharmacology Bulletin highlights that GH001's efficacy is independent of prior antidepressant treatment failures, with Day 8 remission rates ranging from 53.9% to 63.6% among patients with 2 to 5 prior failures, showcasing GH001's unique advantage.
- Long-Term Remission Rate Improvement: At the end of the trial, 6-month remission rates reached 61.5% to 85.7% in the same patient groups, contrasting sharply with the declining remission rates observed in the STAR*D trial with successive treatment failures, suggesting GH001 may offer new hope for patients with extensive treatment histories.
- Advancement of Global Trial Plans: CEO Velichka Valcheva stated that the publication in JAMA Psychiatry provides independent peer-reviewed validation of GH001's Phase 2b findings, supporting the company's efforts to advance GH001 into global pivotal trials, signaling future strategic positioning in the depression treatment landscape.
See More
Helus Pharma Advances New Drug for Anxiety Treatment
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that among 36 patients, those receiving 20 mg achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential for new treatment options for anxiety patients.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of patients suffering from treatment-resistant depression, driving the need for novel rapid-acting therapies, which Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, providing ample resources to support the ongoing advancement of its multi-asset clinical pipeline, ensuring the company maintains a competitive edge in a challenging market.
- Strengthened Leadership: Helus Pharma recently appointed former Pfizer Chief Medical Officer Freda Lewis-Hall to its Board of Directors and as Chair of the Scientific Advisory Committee, leveraging her extensive industry experience to further enhance the company's scientific development and market strategy.
See More
Helus Pharma Advances Mental Health Treatments with Promising Phase 2 Results
- Clinical Trial Progress: Helus Pharma's Phase 2 signal detection study for HLP004 showed that patients receiving the 20 mg dose achieved a mean HAM-A score reduction of 10.4 points (p<0.0001) at six weeks, indicating significant efficacy and potential as an adjunctive treatment for generalized anxiety disorder.
- Strong Market Demand: The global economy loses over $1 trillion annually due to depression and anxiety, with approximately 30% of major depressive disorder patients being treatment-resistant, driving urgent demand for novel therapeutic mechanisms that Helus Pharma aims to address.
- Sufficient Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline and safeguarding its research activities in the mental health sector from financial constraints.
- Enhanced Leadership: The appointment of Dr. Freda Lewis-Hall to Helus Pharma's Board and as Chair of the Scientific Advisory Committee, leveraging her extensive experience at Pfizer, is expected to provide crucial guidance for the company's scientific development and market strategy.
See More
GH Research Reports FY 2025 Financial Results
- Financial Performance: GH Research reported a FY 2025 GAAP EPS of -$0.79, indicating challenges in profitability that could impact investor confidence and stock performance.
- Cash Reserves: As of December 31, 2025, the company held $280.7 million in cash, cash equivalents, and marketable securities, maintaining sufficient liquidity to support future R&D and operations despite the reported losses.
- FDA Progress: GH001 shows robust data ahead of the FDA IND decision, potentially opening new market opportunities; if approved, it could enhance the company's competitiveness in the depression treatment sector.
- Clinical Trial Update: Following the FDA lifting the clinical hold on its depression therapy, GH Research's stock surged, indicating that the upcoming late-stage trial update may further increase market interest in its products.
See More
Helus Pharma Advances Mental Health Drug Development
- Clinical Trial Progress: Helus Pharma's SPL026 showed significant efficacy in a randomized Phase 2 trial for major depressive disorder, with a mean MADRS score reduction of 7.35 in the 21.5 mg dose group among 34 participants, indicating its potential in the mental health sector.
- New Drug Development: The company is advancing HLP003 through Phase 3 trials, which has received FDA Breakthrough Therapy Designation, with preliminary data showing a 100% response rate and 71% remission rate at 12 months, highlighting its importance in treating major depressive disorder.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash reserves, providing strong financial backing for the continued advancement of its multi-asset clinical pipeline, ensuring sustainability for future R&D efforts.
- Market Outlook: As regulatory approvals for mental health drugs draw closer, Helus Pharma and its peers are reshaping the market perception of psychedelic drugs, which is expected to create significant commercial opportunities and enhance market share for the company.
See More
Helus Pharma Advances Psychedelic Drug Clinical Trials
- Clinical Trial Progress: Helus Pharma's SPL026 achieved a mean MADRS difference of -7.35 (p=0.023) in a randomized Phase 2 trial involving 34 participants with major depressive disorder, indicating significant efficacy and potential in the mental health sector.
- Drug Development Strategy: Helus Pharma's HLP003 has received FDA Breakthrough Therapy Designation and is advancing through two pivotal Phase 3 studies, with topline data expected in Q4 2026, showcasing the company's ongoing innovation and competitiveness in depression treatment.
- Financial Support: As of December 31, 2025, Helus Pharma reported $195.1 million in cash, ensuring continued advancement across its multi-asset clinical pipeline, demonstrating a strong financial foundation for R&D efforts.
- Industry Recognition: A consensus statement from the U.S. National Network of Depression Centers indicates that academia is preparing to integrate psychedelics into routine clinical practice, reflecting the growing acceptance of Helus Pharma and its peers in the mental health treatment landscape.
See More
